Loading organizations...

§ Private Profile · An der Goldgrube 12, 55131 Mainz, Germany
Biotechnology company developing and manufacturing mRNA-based immunotherapies and vaccines for oncology and infectious diseases globally.
BioNTech is a biotechnology company that develops mRNA-based immunotherapies and vaccines for cancer and infectious diseases, headquartered in Mainz, Germany. The publicly traded enterprise operates with a workforce of over 4,500 employees and generated approximately €3.8 billion in full-year revenue during 2023. Following the commercial success of its Comirnaty COVID-19 vaccine, which reached nearly $38 billion in peak sales in 2022, the firm achieved a market valuation exceeding $20 billion. The organization advances its clinical pipeline through strategic partnerships with major pharmaceutical corporations, including Pfizer and Sanofi, alongside early financial backing from investors Andreas Strüngmann and Thomas Strüngmann. The business is currently expanding its focus toward investigational antibody-drug conjugates and targeted oncology treatments, aiming for its first cancer therapy approval by 2026. BioNTech was founded in 2008 by Uğur Şahin, Özlem Türeci, and Christoph Huber.
BionTTech has raised $831.2M across 4 funding rounds.
Key people at BionTTech.
BionTTech was founded in 2008 by Ugur Sahin (Co-Founder and CEO) and Christoph Huber (Cofounder & deputy chair supervisory board) and Özlem Türeci (Founder & CMO).
BionTTech has raised $831.2M in total across 4 funding rounds.
Key people at BionTTech.
BionTTech was founded in 2008 by Ugur Sahin (Co-Founder and CEO) and Christoph Huber (Cofounder & deputy chair supervisory board) and Özlem Türeci (Founder & CMO).
BionTTech has raised $831.2M in total across 4 funding rounds.
BionTTech's investors include Richard Hatchett, Fidelity Management & Research Company, BVCF Management, Invus, Jebsen Capital, Mirae Asset, Platinum Asset Management, Redmile Group, Steam Athena Capital, Struengmann Family Office, Yong Liu, Michael Lee.
BionTTech has raised $831.2M across 4 funding rounds. Most recently, it raised $145.0M BioNTech - Other Equity in May 2024.
| Date | Round | Lead Investors | Other Investors | Status |
|---|---|---|---|---|
| May 30, 2024 | $145M Venture Round | Richard Hatchett | — | Announced |
| Jul 9, 2019 | $325M Series B | Fidelity Management & Research Company | BVCF Management, Invus, Jebsen Capital, Mirae Asset, Platinum Asset Management, Redmile Group, Steam Athena Capital, Struengmann Family Office | Announced |
| Jan 4, 2019 | $91.2M Venture Round | Yong LIU | — | Announced |
| Jan 5, 2018 | $270M Series A | Michael LEE | Fidelity Management & Research Company, Invus, Janus Henderson Investors, Struengmann Family Office | Announced |
BioNTech is a global biotechnology company that develops mRNA‑based vaccines and a broad portfolio of immunotherapies and targeted biologics, with a primary focus on oncology and infectious diseases and an integrated model from discovery through manufacturing and commercialization.[2][1]
High‑Level Overview
For a portfolio‑company framing (what BioNTech builds and who it serves): BioNTech builds platform therapeutics—mRNA vaccines and therapeutics, targeted biologics, and immunotherapies—serving patients with cancer and people at risk from serious infectious diseases; its products aim to solve problems of unmet medical need by enabling rapidly programmable vaccines, personalized cancer vaccines and combination immunotherapies to overcome tumor heterogeneity and immune evasion.[2][3] Growth momentum: since founding it has grown from a research startup to a publicly traded, fully integrated biotech with multiple late‑stage programs, major partnerships (e.g., Pfizer; more recent strategic collaborations and acquisitions), and continued pipeline expansion and M&A through 2025.[1][3]
Origin Story
Core Differentiators
Role in the Broader Tech / Biotech Landscape
Quick Take & Future Outlook
If you want, I can: produce a concise investor‑style one‑page, extract key clinical programs and expected milestones, or create a timeline of major partnerships and M&A events through 2025.